INTRODUCTION

Although smoking, a chronic and relapsing addictive trait, has been related to a series of diseases, the prevalence of smoking is still high or increasing in some regions such as in some Asian countries. Smoking leads to nearly 6 million deaths worldwide each year, with more than 5 million of those deaths resulting from direct tobacco use and more than 600,000 non-smokers dying secondary to second-hand smoke exposure. Thus, it is urgent that clinicians develop effective pharmacological methods of smoking cessation. There are several treatments available, such as bupropion, varenicline and nicotine replacement therapy combined with behavioral counseling, but all have a relatively low success rate.

Many factors have been elucidated to explain the modest effectiveness of these medicines; for example, genetic and environmental factors. Twin and family studies have shown that smoking behaviors are highly influenced by genetics. The heritability of smoking cessation is estimated to be ~ 50%. To better understand the molecular mechanism underlying smoking cessation and to improve the strength of pharmacological treatments, researchers have focused on identifying genetic susceptibility factors for various smoking-related phenotypes, including cessation, as investigated in this study.

The dopaminergic reward pathway is widely implicated in the etiology of smoking and the development of nicotine dependence. Consequently, genes with a dopaminergic function have been considered promising candidates in smoking studies. Many studies have implicated a group of candidate genes in smoking behaviors. Nicotine, one of the important components of tobacco smoke, increases the synaptic concentrations of dopamine to a higher concentration than those triggered by natural rewards, which is considered a partial moderating factor of smoking persistence. Therefore, it is reasonable to infer that genes regulating extracellular dopamine concentrations are related to the risk of developing nicotine dependence and the ability to quit smoking. Smokers carrying the variants in those candidate genes associated with an increased synaptic concentration of dopamine are presumed to be more likely to quit smoking.

The dopaminergic pathway consists of three components: dopamine transporters (DAT), dopamine receptors and enzyme targets, which collectively regulate the extracellular dopamine concentration. The DAT is a membrane-spanning protein that removes dopamine from the synapse, a primary way to stop the signal of dopamine neurotransmission. Consequently, numerous studies have concentrated on determining whether...

Many studies have examined the association between SLC6A3 3′-untranslated region (UTR) variable number tandem repeat (VNTR) polymorphism and smoking cessation; however, the results are inconclusive, primarily because of the small-to-moderate size samples. The primary goal of this study was to determine whether this polymorphism has any effect on smoking cessation by a meta-analysis of all reported studies. We adopted a 9-repeat dominant model that considers 9-repeat and non-9-repeat as two genotypes and compared their frequencies in former vs current smokers. Eleven studies with 5480 participants were included. Considering the presence of study heterogeneity and differences in the availability of information from each study, three separate meta-analyses were performed with the Comprehensive Meta-Analysis statistical software (version 2.0). The first meta-analysis provided evidence of association between the 9-repeat genotype and smoking cessation under the fixed-effects model (pooled odds ratio (OR) = 1.13; 95% confidence interval (CI) = 1.01, 1.27; P = 0.037) but not in the random-effects model (pooled OR = 1.11; 95% CI = 0.96, 1.29; P = 0.159). Given the marginal evidence of heterogeneity among studies (P = 0.10; I² = 35.9%), which likely was caused by inclusion of an Asian population treatment study with an opposite effect of the polymorphism on smoking cessation, we excluded the data of this study, revealing a significant association between the 9-repeat genotype and smoking cessation under both the fixed- and random-effects models (pooled OR = 1.15; 95% CI = 1.02, 1.29; P = 0.02 for both models). By analyzing adjusted and unadjusted results, we performed the third meta-analysis, which showed consistently that the 9-repeat genotype was significantly associated with smoking cessation under both the fixed- and random-effects models (pooled OR = 1.17; 95% CI = 1.04, 1.31; P = 0.009 for both models). We conclude that the 3′-UTR VNTR polymorphism is significantly associated with smoking cessation, and smokers with one or more 9-repeat alleles have a 17% higher probability of smoking cessation than smokers carrying no such allele.

The Pharmacogenomics Journal (2016) 16, 10–17; doi:10.1038/tpj.2015.44; published online 7 July 2015
variants in SLC6A3 (also called DAT1), which encode the DAT protein, are associated with smoking behaviors, including cessation. A 40-base-pair number tandem repeat (VNTR) in the 3′ untranslated region (UTR) of the SLC6A3 gene, consisting of 3–16 repeats, is frequently investigated in smoking cessation studies. 

In all reported studies in various ethnic populations, the common alleles of 3′-UTR VNTR polymorphism are the 10-repeat and 9-repeat. Other rare alleles are excluded in certain studies because of their low frequency. Although inconsistent results remain, several functional studies have demonstrated that the 3′-UTR VNTR 9-repeat allele is associated with a risk of reduced DAT availability, which may weaken the dopaminergic function of DAT reuptake with increasing synaptic concentrations of dopamine. Therefore, it is plausible that the 3′-UTR VNTR 9-repeat allele has a vital role in regulating the process of smoking cessation. Sabol et al. first reported a significant supportive association of SLC6A3 3′-UTR VNTR 9-repeat polymorphism with smoking cessation. However, this association was not replicated by follow-up studies. Although negative or totally opposite results have been published, the general results indicate that smokers who carry one or more 9-repeat alleles are more likely to quit smoking than smokers who carry no such allele.

To date, two meta-analyses regarding on the association between SLC6A3 3′-UTR VNTR and smoking cessation have been reported. Selecting three cross-sectional studies for meta-analysis, Munafò et al. found no significant association between this polymorphism and smoking cessation. Stapleton and co-workers reported an independent meta-analysis including five studies with seven cohorts of subjects, performing two separate meta-analyses: one for primary data without adjustment for other variables and another for adjusted data where cohorts within studies were grouped into separate samples, and some odds ratios (ORs) were adjusted for age and sex. Their results from the unadjusted data suggested a trend toward smokers with 9-repeat genotypes having a greater likelihood of smoking cessation (OR = 1.15; 95% confidence interval (CI) = 0.97, 1.37; p = 0.08). From the adjusted data, there existed a statistically significant association of SLC6A3 3′-UTR 9-repeat genotypes with smoking cessation (OR = 1.20; 95% CI = 1.01, 1.37; p = 0.04). Since then, several more studies have been reported, including some with much larger samples; thus, it is important to conduct an updated meta-analysis regarding the effect of this polymorphism on smoking cessation.

**MATERIALS AND METHODS**

**Studies search strategy**

Studies on the relation between SLC6A3 3′-UTR VNTR and smoking behaviors were selected from PubMed. The keywords used were ‘dopamine transporter,’ ‘DAT,’ ‘DAT1,’ ‘SLC6A3,’ ‘smoking,’ ‘nicotine,’ ‘cigarette’ and ‘tobacco.’ These keywords underwent as many reciprocal combinations as possible to identify all the relevant studies. Electronic abstracts were reviewed according to the suggested standard inclusion and exclusion criteria by Moher et al. We also checked the references from the selected studies to find potentially additional studies that were not indexed by PubMed.

**Study inclusion and data extraction**

As reported by other researchers, we used a comparison of former smokers with current smokers to define the phenotype of smoking cessation for those cross-sectional studies. By using a systematic reviewing process with appropriate selection criteria (see Supplementary Figure 1 for details), 13 papers on the association of SLC6A3 3′-UTR VNTR genotypes with smoking cessation were examined for possible inclusion. Because the data used in the study by David et al. consisted of the data from two other independent studies, we excluded the study with the pooled sample and only included the two original studies for our current meta-analysis. Thus, a total of 12 smoking cessation-related studies were included in this meta-analysis, which consisted of 5 cross-sectional studies, 1 no-treatment longitudinal study and 6 treatment longitudinal studies. In the cross-sectional studies, surveyed participants were classified as either former smokers or current smokers. For the longitudinal studies, surveyed participants included only smokers who were followed over time and the proportion of those who have quit at the time of follow-up was used to determine abstinence rate. By using a structured spreadsheet, we extracted the following data from the studies: authors and year of publication, type of study, sample origin, sample size, characteristics of participants (sex and ethnicity) and smoking status categorized according to the 3′-UTR VNTR genotype.

**Classification of phenotypes and genotypes**

In these cross-sectional studies, classification of smoking status was depended on self-report. Both Sabol et al. and Vandenberghe et al. defined current smokers as those who not only had smoked at least 100 cigarettes in their lifetimes but who also smoked either daily or occasionally at the time of the survey and former smokers as those who had smoked at least 100 cigarettes but not smoked immediately before the survey. In two other cross-sectional studies, participants were classified as current or former smokers according to their answers to the following questions: ‘Are you currently smoking?’ and ‘Have you ever smoked regularly?’ Furthermore, the classification method of the non-treatment longitudinal study depended on the responses of participants who were smokers at baseline to the questions 1 year later, and biochemical verification as well.

In the treatment studies, participants included only smokers who were seeking to quit. Except for two studies reported by Ton et al. and Swan et al. which classified subjects on the basis of a self-report, not only were the quitters in other treatment studies identified by self-report, their answers were confirmed by the expiratory carbon monoxide (CO) or salivary cotinine concentration. As smoking cessation is a dynamic process interrupted by relapses, the power to detect both treatment effects and association of the polymorphism with smoking cessation declines as the follow-up time increases after smoking cessation treatment. Between or within these studies, the point-prevalent smoking status was checked at various time frames. Thus, it was relatively difficult to determine which point-prevalent smoking result should be included. For consistency with previous meta-analyses, we used the data of these studies, which were checked at the end of treatment (EOT) for meta-analysis, although O’Gara and colleagues indicated significant evidence of the effect of 3′-VNTR polymorphism on smoking cessation after 1 week post quit day. Furthermore, David et al. reported the abstinence at EOT, and Tashkin et al. presented the smoking status of participants at baseline. In the other two studies, the investigators checked the prevalence of smoking at 12-month follow-up, as well as persistent smoking status. Although the cessation rate at the 12-month follow-up was lower than at the EOT, we used the point-prevalent smoking data from the two studies for this meta-analysis.

The 3′-UTR VNTR 9- and 10-repeat alleles were genotyped in all the studies (Supplementary Table 1). Although rare alleles of 3′-UTR VNTR were excluded because of the very low allele frequencies in some studies, accumulating studies documented a corpus of data without ruling out the rare alleles. Furthermore, a dominant 9-repeat model, which assumes that carriers of the 9-repeat allele have a higher cessation rate than carriers of the no 9-repeat allele did, was adopted in all these studies. In this study, we applied the dominant 9-repeat model where the comparison is 9/9 genotypes including 9/9, 9/10 and 9X (X stands for variants other than 9 or 10 alleles) genotypes compared with 10/10 and other rare genotypes, which was different from the comparison of Stapleton et al. (9/9 and 9/10 genotypes vs 10/10 genotypes).

**Statistical analysis**

Three meta-analyses were carried out to estimate the pooled OR and 95% CI of association of 3′-UTR VNTR 9/9 genotypes with smoking cessation. The first two meta-analyses were based on the raw and unadjusted data extracted from the chosen studies. Given that Sabol et al. described the ORs of the variant in three cohorts stratified by different protocols, and that two of the studies reported two separate ORs adjusted for moderating factors including age and sex, and Swan et al. analyzed the refined data, which included both adjusted and unadjusted data for the third meta-analysis.

Both random-effects and fixed-effects models were used. For the random-effects model, through using DerSimonian and Laird methods, the effect sizes of individual studies were calculated to generate a pooled OR and 95% CI. The effect sizes of the individual studies using the fixed-effects model were pooled using Mantel–Haenszel methods. Compared with the fixed-effects model, which assumes the effect sizes of different
There were different sex ratios in these studies. In particular, the ratio of females only and males only, respectively. Furthermore, some studies\(^{15,16}\) classified the point-prevalent smoking status only by self-report, whereas other studies used both self-report and biochemical verification to define abstinence status. Although there was a wide range of cessation rates, from 20.2 to 61.0%, the three lowest cessation rates (that is, 20.2, 24.9 and 33.1%) were recorded in three longitudinal studies,\(^{20,32,42}\) in which the prevalence of smoking was recorded at a 12-month follow-up, whereas other studies checked smoking status at EOT or a time-point less than 12 months. A total of 2337 (43.3%) of the 5401 participants were identified with 9/* genotypes, which is in line with the frequencies in Caucasian-based studies, ranging from 31.3 to 51.1%, whereas it was only 10.2% in the Asian-based study.\(^{24}\)

**Table 1.** Characteristics of each study included in this meta-analysis (N = 5,401 participants)

| Study name (sample origin) | Publication year | Sample size | % Caucasian | % Male | % Cessation (method of measurement) | 9/* Genotype frequency (%) |
|---------------------------|-----------------|-------------|-------------|--------|-----------------------------------|--------------------------|
| Sabol et al.\(^{19}\) (Israel) | 1999 | 514 | 87.5 | 47.5 | 44.9 (Self-report) | 46.5 |
| Jorm et al.\(^{22}\) (Australia) | 2000 | 409 | 100 | NR | 51.6 (Self-report) | 48.4 |
| Vandenbergh et al.\(^{23}\) (USA) | 2002 | 251 | 89 | NR | 61.0 (Self-report) | 45.8 |
| Lemanyi et al.\(^{39}\) (USA) | 2003 | 418 | 100 | 46.5 | 48.1 (Cotinine verified) | 47.8 |
| O’Gara et al.\(^{33}\) (UK) | 2007 | 563 | 86 | 41.6 | 54.2 (CO verified) | 42.6 |
| Swan et al.\(^{32}\) (USA) | 2007 | 323 | 100 | 37.5 | 33.1 (Self-report) | 51.1 |
| Ton et al.\(^{32}\) (USA) | 2007 | 554 | 93 | 0 (100% Female) | 20.2 (Self-report) | 43.0 |
| David et al. (USA)\(^{40}\) | 2007 | 295 | 100 | 49.7 | 35.9 (Cotinine verified) | 43.7 |
| Han et al.\(^{34}\) (South Korea) | 2008 | 226 | 100 | 40.0 (CO verified) | 10.2 |
| Styn et al.\(^{41}\) (USA) | 2009 | 864 | 100 | 48 | 24.9 (CO verified) | 44.3 |
| Tashkin et al.\(^{41}\) (USA) | 2010 | 621 | >95 | 63.3 | 46.9 (CO and cotinine verified) | 47.2 |
| Gordiev et al.\(^{25}\) (Russia) | 2013 | 364 | 100 | 65.6 | 44.0 (Self-report) | 31.3 |

Abbreviation: NR, not reported. *Percent male and female on the basis of all the samples in the study.

**RESULTS**

Basic information on the included studies

We included 12 studies published between 1999 and 2013 (Table 1). A total of 5401 participants were extracted from the studies, of which the sample sizes ranged from 225 to 864. Except for the study by Han et al.\(^{34}\) which was focused on subjects of Asian origin, all studies were primarily of Caucasian populations. There were different sex ratios in these studies. In particular, the samples of Ton et al.\(^{42}\) and Han et al.\(^{34}\) consisted of females only and males only, respectively. Furthermore, some studies\(^{20,22,23,25,32,42}\) classified the point-prevalent smoking status only by self-report, whereas other studies used both self-report and biochemical verification to define abstinence status. Although there was a wide range of cessation rates, from 20.2 to 61.0%, the three lowest cessation rates (that is, 20.2, 24.9 and 33.1%) were recorded in three longitudinal studies,\(^{20,32,42}\) in which the prevalence of smoking was recorded at a 12-month follow-up, whereas other studies checked smoking status at EOT or a time-point less than 12 months. A total of 2337 (43.3%) of the 5401 participants were identified with 9/* genotypes, which is in line with the frequencies in Caucasian-based studies, ranging from 31.3 to 51.1%, whereas it was only 10.2% in the Asian-based study.\(^{24}\)

Findings from unadjusted data

When analyzing all original data without adjustment for age, sex and ethnicity, the pooled OR in the fixed-effects model was 1.13 (P = 0.037) with 95% CI ranging from 1.01 to 1.27 and in the random-effects model was 1.11 (P = 0.159) with 95% CI of 0.96 to 1.29. Results from the fixed-effects model indicate that one or more 9-repeat alleles confer a higher possibility of smoking abstinence (Table 2 and Figure 1). However, in the first meta-analysis, the P value of the Q test is 0.10 and the P value of the I\(^2\) test is 35.9%, providing marginal evidence of heterogeneity among studies. Under this circumstance, results from the random-effects model appear to be more acceptable, suggesting a trend in all unadjusted data to the genotypes of 3′-UTR VNTR 9-repeat correlating with the ability to achieve smoking cessation.

Of note, only one Asian-based study\(^{34}\) with an opposite result for the polymorphism was included in current meta-analysis. The frequency of 9/* genotypes in this study, by Han et al., was 10.2%, much lower than that in the Caucasian-based studies. Although the sample was relatively small (N = 225), the frequency of 9/* genotypes in this study was similar to the frequencies in other reports on the same ethnic population, where the range is from 9.2 to 16.0%.\(^{37-49}\) Thus, we speculate that inclusion of the study by Han et al.\(^{34}\) might account for the heterogeneity detected among studies in the first meta-analysis.

In the second meta-analysis, we excluded the data from the study by Han et al. to calculate the unadjusted data for Caucasian samples only. The P value of the Q test was increased from 0.10 to 0.48, and the I\(^2\) value was reduced from 35.9 to 0.0% (Table 2), suggesting the absence of heterogeneity among Caucasian populations. From the second meta-analysis, results indicate that the 3′ VNTR 9-repeat genotypes is significantly associated with the ability to achieve smoking cessation (P = 0.02 for both models). Please refer to Table 2 and Figure 2 for details. Because there was no evidence of heterogeneity among the Caucasian-based studies (P = 0.48, I\(^2\) = 0.0%), the fixed- and random-effects model are identical with the pooled OR being 1.15 and the 95% CI ranging from 1.02 to 1.29, suggesting that smokers carrying one or more 3′-UTR VNTR 9-repeat alleles have a 15% increase in the odds of smoking cessation compared with those carrying the non-9-repeat allele.

Although there was no evidence of heterogeneity across 11 studies consisting of 4 cross-sectional surveys and 7 longitudinal studies, we still performed a separate analysis to determine whether different study designs conferred any influence on the final meta-analysis results. Such analyses showed that the pooled OR was 1.16 with 95% CI of 0.94–1.42 in the four cross-sectional surveys (Supplementary Figure 2), and the pooled OR was 1.14 with 95% CI of 0.99–1.32 in the seven longitudinal studies.
These results provide supporting evidence for the robustness of the finding resulted from our pooled analysis. Furthermore, this indicates that our meta-analysis results are not affected by the study design used in original reports.

Findings from adjusted data

In a study including three cohorts stratified by different protocols, Sabol et al. documented the effect of $9^*$ genotypes on smoking cessation with a Cochran–Mantel–Haenszel analysis, demonstrating that the association of $9^*$ genotypes with smoking cessation was more significant than in the pooled data. By performing a logistic regression, Vandenbergh and co-workers reported an adjusted OR for uncontrolled characteristics of participants, although there was no evidence of the association of $9^*$ genotypes with smoking cessation. Similarly, Styn et al. increased the effect size of the variant for abstinence by using a logistic regression method to adjust the moderating factors, including sex, range of age and time of enrollment. We carried out our third meta-analysis by analyzing both adjusted and unadjusted data to provide a more accurate estimated effect of the $9^*$ genotypes on smoking cessation. Consistently, results from the third meta-analysis showed strong evidence that $3'$ VNTR $9^*$ genotypes are significantly associated with smoking cessation ($P = 0.009$ for both models). Both the fixed- and the random-effects models demonstrated that $9^*$ genotypes increase by 17% the likelihood of stopping smoking. For the third meta-analysis, the $P$ value of the $Q$ statistic is 0.58 and the percentage of variation across studies that is not explained by genetic variance is 0, indicating that there existed no heterogeneity among the studies.

Table 2. Results from the meta-analysis for smoking cessation stratified by data set

| Data set         | Cohorts (N) | Estimate of heterogeneity | Fixed-effects model | Random-effects model | $B^*$ |
|------------------|-------------|----------------------------|---------------------|----------------------|-------|
|                  |             | $I^2(\%)$ | $P (Q)$ | Pooled OR | 95% CI | $P (Z)$ | Pooled OR | 95% CI | $P (Z)$ | P(B) |
| Unadjusted data$^b$ | 12          | 35.9  | 0.10   | 1.13     | 1.01, 1.27 | 0.037  | 1.11     | 0.96, 1.29 | 0.159  | 0.009 |
| Unadjusted data$^c$ | 11          | 0.0    | 0.48   | 1.15     | 1.02, 1.29 | 0.020  | 1.15     | 1.02, 1.29 | 0.020  | 0.199 |
| Adjusted data$^d$ | 13          | 0.0    | 0.58   | 1.17     | 1.04, 1.31 | 0.009  | 1.17     | 1.04, 1.31 | 0.009  | 0.197 |

Abbreviations: CI, confidence interval; OR, odds ratio. $^a$Publication bias. $^b$Analysis of raw data extracted from all studies. $^c$Analysis of raw data without data from the Han study. $^d$Analysis of combined unadjusted data with adjusted data.

Figure 1. Forest plot of the first meta-analysis results on pooled effect of $3'$-untranslated region 9-repeat genotypes on smoking cessation. The $Z$ value and $P$ value of each study are presented by rows. The central vertical solid line shows the null hypothesis where the odds ratio (OR) is equal to 1. The OR and 95% confidence interval (CI) of each study are represented by the square and horizontal bar, respectively. The diamond symbol indicates the estimated pooled OR, which was calculated under the fixed-effects model.

Figure 2. Forest plot of the second meta-analysis results on pooled effect of $3'$-untranslated region 9-repeat genotypes on smoking cessation. The $Z$ value and $P$ value of each study are presented by rows. The central vertical solid line shows the null hypothesis, where the odds ratio (OR) is equal to 1. The OR and 95% confidence interval (CI) of each study are represented by the square and horizontal bar, respectively. The diamond symbol marks the estimated pooled OR, which was calculated under the fixed-effects model.

( Supplementary Figure 3). These results provide supporting evidence for the robustness of the finding resulted from our pooled analysis. Furthermore, this indicates that our meta-analysis results are not affected by the study design used in original reports.
The pooled OR and other detailed information of the third meta-analysis are presented in Tables 2 and 3.

Results from sensitivity and accumulative analyses
To determine whether the observed association between 3′ VNTR 9/* genotypes and smoking cessation was significantly biased by the features of a particular study, we performed sensitivity analysis for the last two meta-analyses by removing one study at a time. Based on relative large samples, these two plots showed that the pooled ORs of current meta-analyses were not greatly influenced by each individual study and fluctuated between 1.1 and 1.2 (Figures 3a and b). We also conducted an accumulative analysis for the second meta-analysis to ascertain whether the pooled effect of the 3′ VNTR 9/* genotypes on the higher possibility of smoking cessation differed by publication year. The accumulative

Table 3. Results of meta-analysis for smoking cessation based on adjusted data

| Source | Sample size | Odds ratio | 95% CI  | Weight | Weight (%) |
|--------|-------------|------------|---------|--------|------------|
| Sabol et al. (cancer risk) | 104 | 3.28 | 1.10–9.78 | 3.22 | 1.15 |
| Sabol et al. (personality genetics) | 127 | 1.55 | 0.75–3.20 | 7.33 | 2.62 |
| Sabol et al. (sexual behavior) | 283 | 1.46 | 0.91–2.34 | 17.23 | 6.15 |
| Jorm et al. | 409 | 1.16 | 0.79–1.72 | 25.47 | 9.09 |
| Vandenberg et al. (adjusted data) | 251 | 0.81 | 0.46–1.41 | 12.41 | 4.43 |
| Lerman et al. | 418 | 1.16 | 0.79–1.70 | 26.01 | 9.28 |
| O’Gara et al. | 563 | 1.16 | 0.83–1.62 | 34.07 | 12.16 |
| Swan et al. | 323 | 0.81 | 0.51–1.30 | 17.84 | 6.37 |
| Ton et al. | 554 | 1.37 | 0.90–2.07 | 22.2 | 7.92 |
| David et al. | 295 | 1.26 | 0.78–2.04 | 16.41 | 5.86 |
| Styn et al. (adjusted data) | 864 | 1.04 | 0.76–1.42 | 40.23 | 14.26 |
| Tashkin et al. | 621 | 1.29 | 0.94–1.77 | 38.42 | 13.71 |
| Gordiev et al. | 364 | 1.10 | 0.71–1.72 | 19.36 | 6.91 |
| Pooled analysis | 5176 | 1.17 | 1.04–1.31 | 280.1 | 100 |

Abbreviation: CI, confidence interval. Notes: Test for heterogeneity: $X^2 = 10.46$, d.f. = 12 ($P = 0.58$), $I^2 = 0\%$. Test for overall effect under both fixed-effects and random-effects model: $Z = 2.62$ ($P = 0.009$).
test indicated that the pooled OR of the 3’-UTR VNTR 9/repeat genotypes initially was reduced as publication year increased but became relatively stable after the year 2002 (Supplementary Figure 4).

Identification of possible publication bias

The methods of Egger’s regression and funnel plot were used to evaluate potential publication bias for all the meta-analyses. For the first meta-analysis, the funnel plot is remarkably asymmetrical (Supplementary Figure 5a) and the P value of Egger’s regression is 0.009, suggesting a substantial publication bias. From the first funnel plot, we observed that only one Asian-based study34 deviated from the funnel. As described in the aforementioned sections, we excluded the Han study in the following two meta-analyses. We found that these Caucasian-based studies were symmetrically distributed in the second funnel plot (Supplementary Fig. 5b) and the P value of Egger’s regression is 0.199, indicating no publication bias in the second meta-analysis. For the third meta-analysis, we observed that no studies deviated from the funnel-shaped distribution in the plot, which is shown in Supplementary Figure 5c (Egger’s regression: t = 1.37, d.f. = 11, P = 0.197).

**DISCUSSION**

Although the meta-analysis reported by Munafo et al.25 revealed no significant effect of this polymorphism on smoking cessation, our current study indicates a significant association between 3’-UTR VNTR genotypes and smoking cessation, which is in accordance with the results of the Stapleton study.36 The non-significant association of this polymorphism with smoking cessation reported by Munafo et al. might be a result of the fact that their study analyzed only three studies, all of which had moderate sample sizes, perhaps creating a sample too small to reveal the nature of the link. On the basis of the previous26 and current study data, we conclude that 3’-UTR VNTR 9-repeat genotypes have an important role in smoking cessation in the Caucasian population, with the estimated effect of a 9-repeat allele being a 17% increase in the likelihood of smoking cessation.

Dopamine transporter, one of the important parts of the dopaminergic circuitry, modulates the extracellular dopamine concentration.14-17 The encoding SLC6A3 gene, located on chromosome 5p15, has been associated with addictive behaviors18-21,50 and neuropsychiatric disorders such as attention deficit hyperactivity disorder.51-54 The well-investigated polymorphism of VNTR is located in the 3’-end of the SLC6A3 UTR, influencing both mRNA transcription and stability. Although conflicting results have been described,26,27 numerous functional studies28-31 indicate that a 3’-UTR VNTR 9-repeat allele is associated with the risk of decreased dopamine transporter binding potential or decreased amounts of SLC6A3 transcripts. This implies that under normal circumstances, there exists more abundant synaptic dopamine with longer persistence in the synapse of individuals who carry a 9-repeat allele than those who carry a non-9-repeat allele. Thus, individuals with a 9-repeat allele are less likely to become addicted and find quitting a drug easier. Considering that these conclusions were derived primarily from genic epidemiologic studies, more functional studies are greatly needed. Nevertheless, it is worth noting that the observed association of the 3’-UTR VNTR polymorphism with the higher possibility of abstinence from smoking might result from other functional variants that are in tight linkage disequilibrium with 3’-UTR VNTR polymorphism. For example, several studies55-57 showed that the SLC6A3 promoter and 5’-UTR region were in modest linkage disequilibrium with the 3’-UTR VNTR region, and O’Gara and colleagues55 demonstrated that 3’-UTR VNTR was in linkage disequilibrium with rs27048 and intron 8 VNTR. Besides, Brookes et al.29 indicated that the presence of 3’-UTR VNTR and intron 8 VNTR were highly correlated with the increased amount of SLC6A3 transcript in postmortem midbrain tissue.

When applying the 9-repeat dominant model to all samples, we detected heterogeneity among studies. Because only the Han study34 was focused on an Asian population, we inferred that this study contributed to the detected heterogeneity. We thus excluded this study from our remaining analyses. Further, prior Caucasian-based studies indicated a trend that smokers with one or more 9-repeat alleles were more likely to achieve smoking abstinence. However, Han et al.35 reported a significant trend in the opposite direction, where it was found that a SLC6A3 3’-UTR VNTR 9-repeat genotype was more common in the non-abstinence group than in the abstinence group (χ² = 7.76, P = 0.01). This indicates that smoking cessation may be influenced by the ethnicity of the subjects. For example, although many Caucasian-based studies38-60 documented a significant association of Tag1A A1 allele with ever-smokers, two studies51,62 based on subjects of Asian origin reported that the A2/A2 genotype was significantly associated with smoking risk. Considering the small sample size of the Han study,34 more Asian-based studies with significantly larger sample sizes are greatly needed to determine the effect of the polymorphism on smoking cessation in Asian populations.

Although we found a significant association between the 3’-UTR 9-genotypes and smoking cessation, this finding should be interpreted with caution because of the following potential limitations. First, accruing evidence revealed that the cessation rate declined with time because of the substantial likelihood of smoking relapse.40 The treatment studies we used examined the prevalence of smoking at different time-points, which influenced the power of treatment effects and the association of polymorphism with smoking cessation. In contrast to the former smokers who had mostly quitted many years earlier in those cross-sectional studies, sustained quitters had followed only in short term that might easily contribute to substantial smoking relapse in the longitudinal studies. Furthermore, different diagnostic criteria in defining quitters were used in these two types of studies, where the cross-sectional studies were based on relatively less stringent self-reports of smoking status and the longitudinal studies depended on both self-reports and biochemical verification. The factors might have contributed to the inconsistent results. Second, the different sex ratios and ages of subjects in these studies might impose limitations. An imaging study63 indicated that dopamine release following stimulant exposure tended to be greater in males than in females. In addition, several studies18,64,65 showed, as expected, that females had greater estrogen-induced dopamine activation in the striatum than did males. Thus, females with higher estrogen concentrations might be more easily prevented from addiction. Besides, Styn and colleagues,20 using a logistic regression to adjust the regulatory factors including sex and age, increased the effect of the variant on smoking cessation. Third, because of the lack of sufficient studies on other polymorphisms, we could not examine gene-by-gene and gene-by-environmental interactions, which influence the pathogenesis of polygenic addictive behaviors, including smoking cessation. Lerman et al.39 observed a significant SLC6A3 x DRD2 interactive effect on smoking cessation at the EOT, in that they found that individuals with A2/A2 and 9-repeat genotypes were more likely to stop smoking than were those with A2/A2 and non-9-repeat genotypes. Similarly, Swan et al.32 showed a significant interaction in that participants with A1/* (A1 or A2) and non 9-repeat genotypes were less likely to have stopped smoking at 12-month follow-up. In a fenfluramine test42 in a female cohort, Ton et al. documented a higher cessation rate among carriers of both the SLC6A3 3’-UTR VNTR 9-repeat allele and the DRD2 Tag1A A1 allele. Finally, most included studies failed to screen for underlying comorbid-related addictive and psychiatric disorders in control subjects, which may decrease the reliability of the results reported here.
In summary, results from our meta-analyses reveal a moderate effect of the 3′-UTR VNTR polymorphism on smoking cessation in Caucasians. Compared with smokers with non-9-repeat genotypes, smokers with 9-repeat genotypes have a 17% greater chance of quitting smoking. This indicates that the dopaminergic function of 3′-UTR VNTR 9-repeat genotypes is involved in regulating the process of smoking abstinence in the Caucasian population. Based on prior and current meta-analyses, more well-designed studies, in particular with large samples, are warranted to: (1) explore the molecular mechanism of 3′-UTR VNTR polymorphism for smoking cessation, (2) test the underlying effect of other variants, which are located in SLC6A3 and in LD with the 3′-UTR VNTR polymorphism, on smoking cessation and (3) identify more novel variants potentially associated with smoking cessation. Once robust experimental evidence for the association of genetic variants with smoking cessation is established, it will be more effective to categorize smokers genetically into subgroups for smoking cessation intervention, which is a preliminary but crucial step for future personalized medicine.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
We thank Dr David L Bronson for excellent editing of this manuscript. We also thank Dr Sean P David of Stanford University for providing the original genotyping data reported in his paper (David et al., 2007) to us. This study was supported in part by the Research Center for Air Pollution and Health of Zhejiang University, Ministry of Science and Technology of China (2012AA020405), the National Natural Science Foundation of China grant 81273223, the Young Scientists Fund of National Science Foundation of China (81301140) and the NIH grant DA012844.

REFERENCES
1 WHO. WHO Tobacco Fact sheet N°339 http://www.who.int/mediacentre/fact_sheets/fs339/en/ World Health Organization 2014.
2 Carmelli D, Swan GE, Robinetite D, Fabiels R. Genetic influence on smoking—a study of male twins. N Engl J Med 1992; 327: 829–833.
3 Heath AC, Martin NG. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. Addict Behav 1993; 18: 19–34.
4 Heath AC, Cates R, Martin NG, Meyer J, Hewitt JK, Neale MG et al. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. J Subst Abuse 1993; 5: 221–246.
5 True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N et al. Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277–1287.
6 Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23–31.
7 Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res 1999; 1 (Suppl 2): 551–557.
8 Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 2003; 5: 245–254.
9 Hardie TL, Moss HB, Lynch KG. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. Addict Behav 2006; 31: 2030–2037.
10 David SP, Munafò MR. Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 2008; 9: 1307–1321.
11 Li MD. The genetics of nicotine dependence. Curr Psychiatry Rep 2006; 8: 158–164.
12 Ma Y, Yuan W, Jiang X, Cui WY, Li MD. Updated Findings of the Association and Functional Studies of DRD2/ANKK1 Variants with Addictions. Mol Neurobiol 2014; 51: 281–299.
13 Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010; 35: 702–719.
14 Vandenberghe DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14: 1104–1106.
15 Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905–908.
16 Caron MG. Images in neuroscience. Molecular biology, II. A dopamine transporter mouse knockout. Am J Psychiatry 1996; 153: 1515.
17 Uh GR. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 2003; 18 (Suppl 7): 571–580.
18 Lerman C, Caporaso NE, Audrain J, Maini D, Bowman ED, Lockshin B et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14–20.
19 Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7–13.
20 Styn MA, Nukui T, Romkes M, Perkins K, Land SR, Weissfeld JL. The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 254–261.
21 Hiemstra M, Engels RC, Brody CL, Hu S et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7–13.
22 Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B et al. Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. Am J Med Genet 2000; 96: 331–334.
23 Van der Heijden DJ, Bennett CJ, Grant MD, Strasser AA, O’Connor R, Stautler RL et al. Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res 2002; 4: 333–340.
24 Sieminska A, Buczkowski K, Jassern E, Niedoszytko M, Tkaczk E. Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population. BMC Med Genet 2009; 10: 92.
25 Gordiev M, Engstrom PF, Khassanov R, Moroshek A, Stidikov R, Dgavoronkov V et al. Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patients. Eur Addict Res 2013; 19: 105–111.
26 van Dyck CH, Malston RJ, Jacobsen UK, Seibyl JP, Staley JK, Laruelle M et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nuclear Med 2005; 46: 745–751.
27 Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001; 24: 553–560.
28 Heinz A, Goldman D, Jones DW, Palmour R, Hammer M, Gorey JS et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133–139.
29 Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D’Souza UM. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1070–1076.
30 Mill J, Asherson P, Bowers C, D’Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR. Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114: 975–979.
31 Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001; 1: 152–156.
32 Swan GE, Jack LM, Valdes AM, Ring HZ, Tom CC, Curry SJ et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 2007; 26: 361–368.
33 O’Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 2007; 17: 61–67.
34 Han DH, Joe HK, Na C, Lee YS. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatric genetics 2008; 18: 11–16.
35 Munafò M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583–597.
36 Stapleton JA, Sutherland G, O’Gara C. Association between dopamine transporter gene variants and smoking cessation: a meta-analysis. Addict Biol 2007; 12: 221–227.
37 Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
38 David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013; 108: 2202–2211.
39 Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr., Pinto A et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541–548.
Association of 3'-UTR VNTR in SLC6A3 with smoking cessation

Y Ma et al

© 2016 Macmillan Publishers Limited

The Pharmacogenomics Journal (2016), 10 – 17